EP1749836A3 - Facteur recombinant de croissance de cellules vasculaires - Google Patents

Facteur recombinant de croissance de cellules vasculaires Download PDF

Info

Publication number
EP1749836A3
EP1749836A3 EP06121918A EP06121918A EP1749836A3 EP 1749836 A3 EP1749836 A3 EP 1749836A3 EP 06121918 A EP06121918 A EP 06121918A EP 06121918 A EP06121918 A EP 06121918A EP 1749836 A3 EP1749836 A3 EP 1749836A3
Authority
EP
European Patent Office
Prior art keywords
vegf
endothelial cell
growth factor
cell growth
vascular endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06121918A
Other languages
German (de)
English (en)
Other versions
EP1749836A2 (fr
EP1749836B1 (fr
Inventor
Marc G. Medical Research Building Achen
Andrew F. Wilks
Steven A. Medical Research Building Stacker
Kari Alitalo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vegenics Pty Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Helsinki University Licensing Ltd
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46149776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1749836(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AUPO1825A external-priority patent/AUPO182596A0/en
Priority claimed from AUPO3554A external-priority patent/AUPO355496A0/en
Priority claimed from AUPO4954A external-priority patent/AUPO495497A0/en
Priority claimed from AUPO7435A external-priority patent/AUPO743597A0/en
Priority to EP09162873A priority Critical patent/EP2107109B1/fr
Application filed by Ludwig Institute for Cancer Research Ltd, Helsinki University Licensing Ltd, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Priority to DK09162873.5T priority patent/DK2107109T3/da
Publication of EP1749836A2 publication Critical patent/EP1749836A2/fr
Publication of EP1749836A3 publication Critical patent/EP1749836A3/fr
Publication of EP1749836B1 publication Critical patent/EP1749836B1/fr
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP06121918A 1996-08-23 1997-08-21 Facteur D recombinant de croissance de cellules vasculaires endothéliales Expired - Lifetime EP1749836B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK09162873.5T DK2107109T3 (da) 1996-08-23 1997-08-21 Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)
EP09162873A EP2107109B1 (fr) 1996-08-23 1997-08-21 Facteur D recombinant de croissance de cellules vasculaires endotheliales

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US2375196P 1996-08-23 1996-08-23
AUPO1825A AUPO182596A0 (en) 1996-08-23 1996-08-23 Growth factor
AUPO3554A AUPO355496A0 (en) 1996-11-11 1996-11-11 Growth factor
US3109796P 1996-11-14 1996-11-14
AUPO4954A AUPO495497A0 (en) 1997-02-05 1997-02-05 Growth factors
US3881497P 1997-02-10 1997-02-10
AUPO7435A AUPO743597A0 (en) 1997-06-19 1997-06-19 Growth factor
US5142697P 1997-07-01 1997-07-01
EP97938486A EP0956339B1 (fr) 1996-08-23 1997-08-21 Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
EP02018842A EP1283268A3 (fr) 1996-08-23 1997-08-21 Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP02018842A Division EP1283268A3 (fr) 1996-08-23 1997-08-21 Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09162873A Division EP2107109B1 (fr) 1996-08-23 1997-08-21 Facteur D recombinant de croissance de cellules vasculaires endotheliales

Publications (3)

Publication Number Publication Date
EP1749836A2 EP1749836A2 (fr) 2007-02-07
EP1749836A3 true EP1749836A3 (fr) 2007-08-22
EP1749836B1 EP1749836B1 (fr) 2009-06-17

Family

ID=46149776

Family Applications (4)

Application Number Title Priority Date Filing Date
EP06121918A Expired - Lifetime EP1749836B1 (fr) 1996-08-23 1997-08-21 Facteur D recombinant de croissance de cellules vasculaires endothéliales
EP97938486A Revoked EP0956339B1 (fr) 1996-08-23 1997-08-21 Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
EP09162873A Expired - Lifetime EP2107109B1 (fr) 1996-08-23 1997-08-21 Facteur D recombinant de croissance de cellules vasculaires endotheliales
EP02018842A Withdrawn EP1283268A3 (fr) 1996-08-23 1997-08-21 Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP97938486A Revoked EP0956339B1 (fr) 1996-08-23 1997-08-21 Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
EP09162873A Expired - Lifetime EP2107109B1 (fr) 1996-08-23 1997-08-21 Facteur D recombinant de croissance de cellules vasculaires endotheliales
EP02018842A Withdrawn EP1283268A3 (fr) 1996-08-23 1997-08-21 Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)

Country Status (10)

Country Link
US (14) US6235713B1 (fr)
EP (4) EP1749836B1 (fr)
JP (3) JP2001517075A (fr)
AT (2) ATE306546T1 (fr)
AU (1) AU729880C (fr)
CA (1) CA2263890C (fr)
DE (2) DE69734359T2 (fr)
DK (3) DK1749836T3 (fr)
ES (3) ES2390107T3 (fr)
WO (1) WO1998007832A1 (fr)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP0751992B1 (fr) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Facteur 2 de croissance endotheliale vasculaire
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
WO1997012972A2 (fr) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Genes regules et leurs utilisations
WO1997033904A1 (fr) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
AU733322B2 (en) * 1996-07-15 2001-05-10 Chugai Seiyaku Kabushiki Kaisha Novel VEGF-like factor
CA2263890C (fr) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
KR100628697B1 (ko) * 1997-12-24 2006-09-28 루드빅 인스티튜트 포 캔서 리서치 맥관 내피 성장인자 ｄ를 발현하는 발현 벡터와 셀라인,및 흑색종을 치료하는 방법
AU765888B2 (en) * 1997-12-24 2003-10-02 Vegenics Limited Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
EP0984063A3 (fr) * 1998-08-31 2000-08-16 Eli Lilly And Company Gene et proteine apparentee au vegf
US20030082670A1 (en) * 1998-09-30 2003-05-01 Ulf Eriksson Platelet-derived growth factor C, DNA coding therefor, and uses thereof
US20040053837A1 (en) * 1998-09-30 2004-03-18 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
US20030211994A1 (en) * 1998-09-30 2003-11-13 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
ATE489108T1 (de) 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ES2229788T3 (es) * 1998-10-26 2005-04-16 Ludwig Institute For Cancer Research Uso del gen o proteina vegf-c o vegf-d para prevenir la restenosis.
EP1568375A1 (fr) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Utilisation des protéines VEGF-C ou VEGF-D pour la prévention de la resténose
JP2002534061A (ja) 1998-11-10 2002-10-15 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子ｄ、それをコードするｄｎａ、及びその利用法
CA2354325C (fr) * 1998-12-07 2011-08-16 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance
CA2355896A1 (fr) 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Anticorps antifacteur de croissance endotheliale vasculaire tronque et leur utilisation
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
AU778412B2 (en) * 1998-12-22 2004-12-02 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
WO2000058511A1 (fr) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
CA2368670C (fr) * 1999-03-26 2012-06-05 Chitra Suri Modulation de la permeabilite vasculaire au moyen d'activateurs de recepteurs tie2
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
WO2001012669A1 (fr) * 1999-08-16 2001-02-22 Universita' Degli Studi Di Siena Vegf-d et utilisation angiogenique de celui-ci
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US7045133B2 (en) 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
WO2001057008A1 (fr) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft Derives de 2-benzothiazolyle uree et leur utilisation en tant qu'inhibiteurs de proteine kinase
AU2001239884B2 (en) * 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
DK1259248T3 (da) * 2000-03-02 2005-04-11 Ludwig Inst Cancer Res Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
CA2401665A1 (fr) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Procedes de traitement, d'examen et de detection de cancers exprimant le facteur d de croissance endotheliale vasculaire
AU2006201128B2 (en) * 2000-03-02 2009-05-28 Vegenics Limited Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
EP1274720A4 (fr) 2000-04-12 2004-08-18 Human Genome Sciences Inc Proteines fusionnees a l'albumine
AU2001264565B2 (en) * 2000-05-03 2006-12-07 Vegenics Limited A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
JP2004527462A (ja) * 2000-11-01 2004-09-09 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血管新生活性のｉｎｖｉｖｏ刺激
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (fr) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4 (vegfr-3) utilise comme cible pour l'imagerie des tumeurs et le traitement antitumoral
US20020164624A1 (en) * 2001-02-12 2002-11-07 Waldemar Debinski VEGF-D expression in brain cancer
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
CA2452865A1 (fr) * 2001-06-07 2002-12-12 Skinmedica, Inc. Milieu de culture cellulaire conditionne et utilisations de ce milieu
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
US7514261B2 (en) * 2001-08-09 2009-04-07 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
AU2002363369B2 (en) 2001-10-15 2008-08-21 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
WO2003104428A2 (fr) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene s'exprimant de façon differentielle dans le cancer du sein et de la vessie et polypeptides codes
CA2478063A1 (fr) * 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Genes de cellules endotheliales sanguines et lymphatiques
US7510714B2 (en) * 2002-04-01 2009-03-31 Trustees Of Dartmouth College Methods for modulating angiogenesis
US7241446B2 (en) * 2002-04-01 2007-07-10 Trustees Of Dartmouth College Methods for modulating angiogenesis via VEGF
AU2003228762A1 (en) * 2002-05-03 2003-11-17 Ludwig Institute For Cancer Research Preventing secondary lymphedema with vegf-d dna
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
EP1594527A2 (fr) * 2003-02-04 2005-11-16 Ludwig Institute For Cancer Research Modulation vegf-b et pdgf de cellules souches
EP1635860A2 (fr) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Utilisation de vegf-c ou de vegf-d en chirurgie reconstructive
WO2005016963A2 (fr) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Ligands de recepteur 3 du facteur de croissance des cellules endotheliales de liaison a l'heparine
US20070110744A1 (en) * 2003-09-08 2007-05-17 Kari Alitalo Lymphatic and blood endothelial cell genes
US7284505B1 (en) 2003-11-03 2007-10-23 Paxton Stephen E Skijor system
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
KR20070006714A (ko) * 2003-12-29 2007-01-11 센텔리옹 에스아에스 관상 동맥 또는 말초 허혈 치료
US20050142161A1 (en) * 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
WO2005087812A1 (fr) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Substances d'anticorps polyvalentes et procedes pour la famille vegf/pdgf des facteurs de croissance
WO2005087177A2 (fr) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Anticorps chimeriques anti-vegf-d et anticorps humanises anti-vegf-d et leurs procedes d'utilisation
WO2005093098A1 (fr) * 2004-03-12 2005-10-06 Ludwig Institute For Cancer Research Sensibilité différentielle aux médicaments
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
EP1869075B1 (fr) 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Methodes et compostions anti-angiogeniques
WO2007022287A2 (fr) 2005-08-15 2007-02-22 Vegenics Limited Vegf-a modifié aux propriétés angiogéniques améliorées
TW200732347A (en) 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
ATE476986T1 (de) 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
EP2125895B1 (fr) 2007-02-02 2015-04-08 Vegenics Pty Ltd Antagoniste du recepteur de facteurs de croissance pour l'allo-immunite de greffe d'organe et l'arteriosclerose
US20080267924A1 (en) * 2007-02-07 2008-10-30 Vegenics Limited Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
US7811776B2 (en) 2007-12-05 2010-10-12 University Of Cincinnati Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
WO2009143584A1 (fr) * 2008-05-30 2009-12-03 Vegenics Limited Traitement de l’œdème pulmonaire
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
US8255807B2 (en) * 2008-12-23 2012-08-28 Ganz Item customization and website customization
WO2010111746A1 (fr) * 2009-04-03 2010-10-07 Vegenics Limited Anticorps anti-vegf-d
WO2011056494A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Combinaisons d'antagonistes de la kinase-1 du type récepteur de l'activine et d'antagonistes vegfr3
WO2011106697A1 (fr) 2010-02-25 2011-09-01 Schepens Eye Research Institute Compositions thérapeutiques pour le traitement de la maladie de l'œil sec
WO2011154308A1 (fr) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. Nouvelles compositions et procédés de thérapie cellulaire dans le traitement de la cirrhose
WO2012088563A1 (fr) * 2010-11-24 2012-07-05 Vegenics Pty Limited Formes spécifiques du vegfr-2 de vegf-d et vegf-c et utilisations associées
WO2012154983A2 (fr) 2011-05-10 2012-11-15 Biocare Medical, Llc Systèmes et procédés pour des anticorps anti-pax8
US9415090B2 (en) * 2011-06-01 2016-08-16 Universität Heidelberg VEGF-D/VEGFR2/3-mediated regulation of dendrites
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
EP3572515B1 (fr) 2012-07-30 2021-07-21 Trophogen Inc. Superagonistes à action de longue durée des hormones glycoprotéines
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
WO2014100220A2 (fr) 2012-12-18 2014-06-26 Biocare Medical, Llc Systèmes de cocktail d'anticorps et procédés de classification de sous-types histologiques dans le cancer du poumon
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
EP2962113B1 (fr) 2013-02-28 2019-04-03 Biocare Medical, LLC Anticorps anti-p40, systèmes et procédés
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
CN105873602A (zh) 2013-11-05 2016-08-17 特洛佛根股份有限公司 糖蛋白激素长效超激动剂
EP3924367A4 (fr) * 2019-04-04 2022-10-12 Sree Chitra Tirunal Institute for Medical Sciences and Technology Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée
US20240150807A1 (en) * 2021-03-10 2024-05-09 Sumitomo Pharma Co., Ltd. Method for Producing Cysteine Knot Protein
WO2024259161A2 (fr) * 2023-06-14 2024-12-19 Yale University Procédés et compositions pour le traitement de troubles de la respiration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024473A1 (fr) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Facteur 2 de croissance endotheliale vasculaire
WO1997012972A2 (fr) * 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Genes regules et leurs utilisations
WO1998002543A1 (fr) * 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968778A (en) 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US6207454B1 (en) * 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5476839A (en) * 1990-07-10 1995-12-19 Incyte Pharmaceuticals, Inc. Basophil granule proteins
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
JPH05271294A (ja) 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
ATE157672T1 (de) 1992-07-27 1997-09-15 Pfizer Calcium-kanal blockierende polypeptide aus agelenopsis aperta
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
DE4423098A1 (de) 1994-07-01 1996-01-04 Hoechst Ag Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
JPH08185216A (ja) 1994-12-28 1996-07-16 Meidensha Corp 工具姿勢パラメータ設定方法及びロボット制御装置
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
JPH11500139A (ja) 1995-03-02 1999-01-06 アムラド・オペレイションズ・プロプライエタリー・リミテッド 新規成長因子およびそれをコードする遺伝子配列
EP0873348A4 (fr) 1995-06-06 2000-11-08 Human Genome Sciences Inc Facteur de croissance 3 de l'endothelium vasculaire humain
ES2202469T5 (es) * 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
JP3843488B2 (ja) 1996-06-06 2006-11-08 アイシン・エィ・ダブリュ株式会社 自動変速機の制御装置
CA2263890C (fr) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
WO1998024811A2 (fr) 1996-12-06 1998-06-11 Zymogenetics, Inc. Facteur de croissance endotheliale vasculaire
US20020165174A1 (en) * 1997-01-31 2002-11-07 Gill Parkash S. Methods and compositions for antisense VEGF oligonucleotides
KR100628697B1 (ko) 1997-12-24 2006-09-28 루드빅 인스티튜트 포 캔서 리서치 맥관 내피 성장인자 ｄ를 발현하는 발현 벡터와 셀라인,및 흑색종을 치료하는 방법
DE19817835C2 (de) 1998-04-22 2000-05-18 Billhofer Maschf Gmbh Sichtkaschiervorrichtung
DE19823359C1 (de) 1998-05-15 1999-10-07 Francotyp Postalia Gmbh Vorrichtung zum Bedrucken von Postgut
CA2355896A1 (fr) 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Anticorps antifacteur de croissance endotheliale vasculaire tronque et leur utilisation
WO2001012669A1 (fr) * 1999-08-16 2001-02-22 Universita' Degli Studi Di Siena Vegf-d et utilisation angiogenique de celui-ci
EP1635860A2 (fr) 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Utilisation de vegf-c ou de vegf-d en chirurgie reconstructive
US20070212390A1 (en) 2005-09-22 2007-09-13 Ludwig Institute For Cancer Research Protease-resistant forms of VEGF-D, method of making and method of use
FR2987282B1 (fr) 2012-02-24 2017-12-29 Fonds De L'espci Georges Charpak Microcanal avec dispositif d'ouverture et/ou fermeture et/ou pompage
US9405291B2 (en) 2012-07-31 2016-08-02 Fisher-Rosemount Systems, Inc. Systems and methods to monitor an asset in an operating process unit
US9516755B2 (en) 2012-12-28 2016-12-06 Intel Corporation Multi-channel memory module
US9426605B2 (en) 2013-10-10 2016-08-23 Yahoo! Inc. Cross device information exchange using gestures and locations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024473A1 (fr) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Facteur 2 de croissance endotheliale vasculaire
WO1997012972A2 (fr) * 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Genes regules et leurs utilisations
WO1998002543A1 (fr) * 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ORLANDINI M ET AL: "IDENTIFICATION OF A C-FOS INDUCED GENE THAT IS RELATED TO THE PLATELET-DERIVED GROWTH FACTOR/VASCULAR ENDOTHELIAL GROWTH FACTOR FAMILY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 93, no. 21, 15 October 1996 (1996-10-15), pages 11675 - 11680, XP002029340, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU729880C (en) 2001-11-08
US20080145366A1 (en) 2008-06-19
US7662932B2 (en) 2010-02-16
US7785803B2 (en) 2010-08-31
US20090087905A1 (en) 2009-04-02
US8227410B2 (en) 2012-07-24
US8759286B2 (en) 2014-06-24
US20040175730A1 (en) 2004-09-09
US20110281799A1 (en) 2011-11-17
ES2390107T3 (es) 2012-11-06
US20120322105A1 (en) 2012-12-20
US7928061B2 (en) 2011-04-19
CA2263890C (fr) 2013-05-14
JP2009291198A (ja) 2009-12-17
DE69739469D1 (de) 2009-07-30
US20060177428A1 (en) 2006-08-10
US20030114658A1 (en) 2003-06-19
EP2107109A1 (fr) 2009-10-07
ES2251740T3 (es) 2006-05-01
HK1025789A1 (en) 2000-11-24
WO1998007832A1 (fr) 1998-02-26
EP0956339A1 (fr) 1999-11-17
US20080058258A1 (en) 2008-03-06
US20080070831A1 (en) 2008-03-20
ATE434034T1 (de) 2009-07-15
US6689580B1 (en) 2004-02-10
US7122654B2 (en) 2006-10-17
AU4079697A (en) 1998-03-06
US20130345409A1 (en) 2013-12-26
US7410639B2 (en) 2008-08-12
US8445234B2 (en) 2013-05-21
EP1749836A2 (fr) 2007-02-07
DK0956339T3 (da) 2006-01-30
US7871798B2 (en) 2011-01-18
EP1283268A3 (fr) 2004-01-02
EP1749836B1 (fr) 2009-06-17
JP2007167072A (ja) 2007-07-05
ES2327440T3 (es) 2009-10-29
ATE306546T1 (de) 2005-10-15
CA2263890A1 (fr) 1998-02-26
JP2001517075A (ja) 2001-10-02
US20030125537A1 (en) 2003-07-03
DK2107109T3 (da) 2012-09-24
US20070298493A1 (en) 2007-12-27
DE69734359D1 (de) 2006-02-23
EP0956339A4 (fr) 2000-08-23
DK1749836T3 (da) 2009-08-31
EP1283268A2 (fr) 2003-02-12
EP2107109B1 (fr) 2012-06-20
AU729880B2 (en) 2001-02-15
US6235713B1 (en) 2001-05-22
DE69734359T2 (de) 2006-07-06
EP0956339B1 (fr) 2005-10-12

Similar Documents

Publication Publication Date Title
EP1283268A3 (fr) Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)
EP2151454A3 (fr) Facteur de croissance D d'origine plaquettaire, l'ADN codant pour celui-ci et ses utilisations
CA2095153A1 (fr) Modification genetique de cellules endotheliales
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
EP1308515A3 (fr) Facteur VIII porcin
EP0897987A3 (fr) Sécretion de protéine humaine associée au peptide-signal de l' interferon gamma
AU1096595A (en) Thrombin mutants
ZA943464B (en) Vascular endothelial growth factor 2
HU9402143D0 (en) Dna sequences encoding novel growth/differentiation factors
WO1995005452A3 (fr) Compositions et procedes ameliores pour l'administration de molecuiles a activite biologique a l'aide de cellules modifiees genetiquement comprises dans des capsules biocompatibles immuno-isolatrices
CA2005016A1 (fr) Fragment d'adn contenant un promoteur de site de l'elongation de la chaine de polypeptide humaine de facteur-1.alpha. et plamisde d'expression contenant ce fragment d'adn
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
EP0266190A3 (en) Expression of protein c
AU2001254624A1 (en) Human coagulation factor vii variants
AU3192889A (en) T cell activation markers
IL70776A (en) Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides
AU3498189A (en) Fibronectin binding protein
AU7869487A (en) Expression of biologically active factor XIII
WO2001025438A3 (fr) Homologues d'interferons alpha
EP0290948A3 (fr) Oncostatin M et nouvelles compositions ayant une activité anti-néoplastiquée
EP1080724A4 (fr) Compositions destinees a diminuer l'activite mtp
IL129139A0 (en) Vertebrate smoothened proteins
WO2001040257A3 (fr) Polypeptides cytokines et acides nucleiques
WO2001053324A3 (fr) Nouveaux peptides haptotactiques
WO2001025437A3 (fr) Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0956339

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1283268

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20070404

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/49 20060101ALI20070718BHEP

Ipc: C07K 1/14 20060101ALI20070718BHEP

Ipc: C12N 15/18 20060101ALI20070718BHEP

Ipc: C12N 5/10 20060101ALI20070718BHEP

Ipc: C12N 1/21 20060101AFI20070718BHEP

Ipc: C07K 14/475 20060101ALI20070718BHEP

Ipc: C07K 14/52 20060101ALI20070718BHEP

Ipc: C12N 15/63 20060101ALI20070718BHEP

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20080407

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VEGENICS LIMITED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1283268

Country of ref document: EP

Kind code of ref document: P

Ref document number: 0956339

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69739469

Country of ref document: DE

Date of ref document: 20090730

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2327440

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090617

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090617

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090617

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091017

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

26 Opposition filed

Opponent name: CHUGAI SEIYAKU KABUSHIKI KAISHA

Effective date: 20100317

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090918

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090617

PLBD Termination of opposition procedure: decision despatched

Free format text: ORIGINAL CODE: EPIDOSNOPC1

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090821

PLBM Termination of opposition procedure: date of legal effect published

Free format text: ORIGINAL CODE: 0009276

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION PROCEDURE CLOSED

27C Opposition proceedings terminated

Effective date: 20110506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20130823

Year of fee payment: 17

Ref country code: IE

Payment date: 20130819

Year of fee payment: 17

Ref country code: CH

Payment date: 20130826

Year of fee payment: 17

Ref country code: SE

Payment date: 20130822

Year of fee payment: 17

Ref country code: DK

Payment date: 20130819

Year of fee payment: 17

Ref country code: ES

Payment date: 20130828

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20130823

Year of fee payment: 17

Ref country code: FR

Payment date: 20130820

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20130823

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69739469

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20140831

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140821

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69739469

Country of ref document: DE

Effective date: 20150303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140822

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150303

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140821

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140901

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140821

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140822